特奈特普酶
医学
改良兰金量表
冲程(发动机)
安慰剂
纤溶剂
优势比
灌注
灌注扫描
大脑中动脉
随机化
置信区间
随机对照试验
麻醉
内科学
组织纤溶酶原激活剂
外科
溶栓
缺血
心肌梗塞
缺血性中风
替代医学
病理
工程类
机械工程
作者
Gregory W. Albers,Mouhammad Jumaa,Barbara Purdon,Syed Zaidi,Christopher Streib,Ashfaq Shuaib,Navdeep Sangha,Minjee Kim,Michael T. Froehler,Neil Schwartz,Wayne M. Clark,Charles E. Kircher,Ming Yang,Lori Massaro,Xiao-Yu Lü,Gregory A. Rippon,Joseph P. Broderick,Kenneth Butcher,Maarten G. Lansberg,David S. Liebeskind
标识
DOI:10.1056/nejmoa2310392
摘要
Tenecteplase therapy that was initiated 4.5 to 24 hours after stroke onset in patients with occlusions of the middle cerebral artery or internal carotid artery, most of whom had undergone endovascular thrombectomy, did not result in better clinical outcomes than those with placebo. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by Genentech; TIMELESS ClinicalTrials.gov number, NCT03785678.).
科研通智能强力驱动
Strongly Powered by AbleSci AI